Literature DB >> 28776140

Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?

Mariangela Allocca1, Gionata Fiorino1, Silvio Danese2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28776140     DOI： 10.1007/s10620-017-4693-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?

Authors:  Gionata Fiorino; Maria Fazio; Silvio Danese
Journal:  Expert Rev Clin Immunol       Date:  2016-02-08       Impact factor: 4.473

2.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

Authors:  Martin Schiestl; Thomas Stangler; Claudia Torella; Tadej Cepeljnik; Hansjörg Toll; Roger Grau
Journal:  Nat Biotechnol       Date:  2011-04       Impact factor: 54.908

3.  ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

Authors:  Silvio Danese; Fernando Gomollon
Journal:  J Crohns Colitis       Date:  2013-04-25       Impact factor: 9.071

4.  Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

Authors:  F Schnitzler; H Fidder; M Ferrante; M Noman; I Arijs; G Van Assche; I Hoffman; K Van Steen; S Vermeire; P Rutgeerts
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

5.  Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.

Authors:  Lisa J T Smits; Anna Grelack; Lauranne A A P Derikx; Dirk J de Jong; Aura A J van Esch; Ronald S Boshuizen; Joost P H Drenth; Frank Hoentjen
Journal:  Dig Dis Sci       Date:  2017-06-30       Impact factor: 3.199

6.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

7.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.

Authors:  Won Park; Pawel Hrycaj; Slawomir Jeka; Volodymyr Kovalenko; Grygorii Lysenko; Pedro Miranda; Helena Mikazane; Sergio Gutierrez-Ureña; MieJin Lim; Yeon-Ah Lee; Sang Joon Lee; HoUng Kim; Dae Hyun Yoo; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.